Patents by Inventor Oded FOREMAN

Oded FOREMAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ASSAYS FOR DETECTING T CELL IMMUNE SUBSETS AND METHODS OF USE THEREOF
    Publication number: 20210109099
    Abstract: The present disclosure provides methods for measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in a sample containing cancer cells and lymphocytes obtained from a subject by labeling lymphocytes that show CD4 expression in the sample, then labeling lymphocytes that show OX40 expression in the sample, then labeling lymphocytes that show Foxp3 expression in the sample, then measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in the sample. Further provided are methods for determining the prognosis of a subject, predicting responsiveness of a subject having cancer to an OX40 agonist treatment, and methods for treating or delaying progression of cancer based on the number of CD4+ OX40+ Foxp3+ lymphocytes in a sample.
    Type: Application
    Filed: October 20, 2020
    Publication date: April 15, 2021
    Applicant: Genentech, Inc.
    Inventors: Felix CHU, Oded FOREMAN, James ZIAI
  • Assays for detecting T cell immune subsets and methods of use thereof
    Patent number: 10845364
    Abstract: The present disclosure provides methods for measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in a sample containing cancer cells and lymphocytes obtained from a subject by labeling lymphocytes that show CD4 expression in the sample, then labeling lymphocytes that show OX40 expression in the sample, then labeling lymphocytes that show Foxp3 expression in the sample, then measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in the sample. Further provided are methods for determining the prognosis of a subject, predicting responsiveness of a subject having cancer to an OX40 agonist treatment, and methods for treating or delaying progression of cancer based on the number of CD4+ OX40+ Foxp3+ lymphocytes in a sample.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: November 24, 2020
    Assignee: Genentech, Inc.
    Inventors: Felix Chu, Oded Foreman, James Ziai
  • ASSAYS FOR DETECTING T CELL IMMUNE SUBSETS AND METHODS OF USE THEREOF
    Publication number: 20180238878
    Abstract: The present disclosure provides methods for measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in a sample containing cancer cells and lymphocytes obtained from a subject by labeling lymphocytes that show CD4 expression in the sample, then labeling lymphocytes that show OX40 expression in the sample, then labeling lymphocytes that show Foxp3 expression in the sample, then measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in the sample. Further provided are methods for determining the prognosis of a subject, predicting responsiveness of a subject having cancer to an OX40 agonist treatment, and methods for treating or delaying progression of cancer based on the number of CD4+ OX40+ Foxp3+ lymphocytes in a sample.
    Type: Application
    Filed: December 21, 2017
    Publication date: August 23, 2018
    Applicant: Genentech, Inc.
    Inventors: Felix Chu, Oded Foreman, James Ziai
  • ANIMAL MODEL FOR NEPHROPATHY AND AGENTS FOR TREATING THE SAME
    Publication number: 20170339928
    Abstract: A non-human transgenic animal expressing ApoL1 is provided as well as a method for generating the same. Also provided is a method for identifying an agent capable of reducing the progression of an ApoL1 mediated nephropathy. Furthermore, an isolated antibody is provided which binds to the human variants of ApoL1.
    Type: Application
    Filed: May 10, 2017
    Publication date: November 30, 2017
    Applicant: Genentech, Inc.
    Inventors: Deanna Grant Wilson, Oded Foreman, Andrew Peterson, Xiaohui Wen, Suzanna J. Scales
  • ASSAYS FOR DETECTING T CELL IMMUNE SUBSETS AND METHODS OF USE THEREOF
    Publication number: 20160161485
    Abstract: The present disclosure provides methods for measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in a sample containing cancer cells and lymphocytes obtained from a subject by labeling lymphocytes that show CD4 expression in the sample, then labeling lymphocytes that show OX40 expression in the sample, then labeling lymphocytes that show Foxp3 expression in the sample, then measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in the sample. Further provided are methods for determining the prognosis of a subject, predicting responsiveness of a subject having cancer to an OX40 agonist treatment, and methods for treating or delaying progression of cancer based on the number of CD4+ OX40+ Foxp3+ lymphocytes in a sample.
    Type: Application
    Filed: November 2, 2015
    Publication date: June 9, 2016
    Applicant: GENENTECH, INC.
    Inventors: Felix CHU, Oded FOREMAN, James ZIAI